RACHEL SANDERSON: Open Payments
NPI 1497201677 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,508 in 100 payments from 12 companies in 2025. Trend: 2023 $1,120 · 2024 $1,119 · 2025 $1,508
Food & beverage: $1,449Education: $59
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 24 | $304 |
| ABBVIE INC. | 18 | $280 |
| PFIZER INC. | 17 | $236 |
| Vanda Pharmaceuticals Inc. | 10 | $156 |
| Lilly USA, LLC | 10 | $148 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $68 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $52 |
| Astellas Pharma US Inc | 2 | $50 |
Products named: VRAYLAR, Ozempic, NURTEC ODT, FANAPT, MOUNJARO, REXULTI, JARDIANCE, VOQUEZNA.
Industry payments across IN — which companies pay providers there.
